Amir Ganun - Endymed VP Marketing
| ENDY Stock | 295.00 1.00 0.34% |
Insider
Amir Ganun is VP Marketing of Endymed
| Age | 49 |
| Phone | 855 363 9633 |
| Web | https://www.endymed.com |
Endymed Management Efficiency
The company has return on total asset (ROA) of 0.0385 % which means that it generated a profit of $0.0385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2146 %, meaning that it generated $0.2146 on every $100 dollars invested by stockholders. Endymed's management efficiency ratios could be used to measure how well Endymed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yaacov Kagan | Elbit Systems | N/A | |
| Eli Shani | Teva Pharmaceutical Industries | N/A | |
| Elias MD | Opko Health | 72 | |
| Andrew Weil | Teva Pharmaceutical Industries | 52 | |
| Bilha Shapira | Elbit Systems | 66 | |
| Janet Vergis | Teva Pharmaceutical Industries | 54 | |
| Yifat Esq | Kamada | 47 | |
| Ronit SatchiFainaro | Teva Pharmaceutical Industries | 46 | |
| Iris Avner | Tower Semiconductor | 54 | |
| Jerry Neal | Tower Semiconductor | 74 | |
| Eran Nir | Kamada | 51 | |
| MBA MBA | Opko Health | 75 | |
| Amir Weiss | Teva Pharmaceutical Industries | 46 | |
| Yoav Chelouche | Tower Semiconductor | 66 | |
| Abbas Hussain | Teva Pharmaceutical Industries | 54 | |
| Dani Ashkenazi | Tower Semiconductor | 60 | |
| Arie Gutman | Opko Health | 69 | |
| Ariella Raban | Kamada | 48 | |
| Kathleen Veit | Teva Pharmaceutical Industries | N/A | |
| Jon MD | Opko Health | 68 | |
| James DeMarco | Opko Health | N/A | |
Management Performance
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0385 |
Endymed Leadership Team
Elected by the shareholders, the Endymed's board of directors comprises two types of representatives: Endymed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endymed. The board's role is to monitor Endymed's management team and ensure that shareholders' interests are well served. Endymed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endymed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Levtzler, Clinical VP | ||
| Rami Aviram, Vice President - Finance | ||
| Yossi CPA, Chief Officer | ||
| Sima Weissman, VP RD | ||
| Bill Scott, Pres Inc | ||
| Amir Ganun, VP Marketing |
Endymed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endymed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0385 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 1.85 M | |||
| Shares Outstanding | 13.76 M | |||
| Shares Owned By Insiders | 58.11 % | |||
| Price To Book | 0.70 X | |||
| Price To Sales | 1.52 X | |||
| Revenue | 21.78 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Endymed Stock
Endymed financial ratios help investors to determine whether Endymed Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Endymed with respect to the benefits of owning Endymed security.